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1. Abbreviations 
AGA - appropriate for gestational age 
ANOVA = analysis of variance 
APIB - assessment of premature infants’ 
behaviour 
BBB - blood-brain-barrier 
CNS - central nervous system 
CP - cerebral palsy 
DAB - 3’3 diaminobenzidine 
EPC - endothelial progenitor cell 
FGR - fetal growth restriction  
fig - figure 
GA - gestational age 
GABA - gamma-aminobutyric acid 
GM-IVH- germinal matrix-intraventricular 
haemorrhage 
HRP - horseradish peroxidase 
IHC – immunohistochemistry 
 
IUGR - intrauterine growth restriction 
IVH - intraventricular hemorrhage  
min - minutes 
MMP – matrix metalloproteinase  
MRI - magnetic resonance imaging  
NS - non-significant 
NVU - neurovascular unit 
PAP – peroxidase-anti-peroxidase 
PBS - phosphate-buffered saline 
PVWM - periventricular white matter 
PWMI - periventricular white matter injury 
SCWM - subcortical white matter 
SEM - standard error of the mean 
SGA- small for gestational age 
SUAL - single umbilical artery ligation 
SVZ - subventricular zone 
UA - umbilical artery 
VEGF = vascular endothelial growth factor 
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2. Abstract 
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Programme in Medicine 
Title: An ontogeny study of cerebral vascular maturation in a sheep model of fetal growth restriction 
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Background: In fetal growth restriction (FGR), the fetus fails to reach its genetically determined 
growth potential during gestation. It is most commonly caused by placental insufficiency that leads 
to chronic hypoxia in utero, affecting neurodevelopment.  
Aims: In this experimental ontogeny study, we aim to examine the expression and distribution of 
laminin, VEGF, MMP9, endoglin and Ki67 in the developing, growth-restricted ovine brains and 
compare the distribution to appropriately grown, gestational-age matched control animals. 
Methods: A growth restricted group and a control group of fetal sheep at 115, 125 and 145 (term) 
days of gestation were studied in this project. Sections of the periventricular white matter, subcortical 
white matter and subventricular zone were stained with immunohistochemistry.  
Results: The majority of the immunohistochemical markers used in this study showed no statistically 
significant differences between the FGR group and the control group at the gestational ages and the 
brain regions examined. Nonetheless, we found significant differences in the blood vessel 
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morphology parameters and blood vessel density between the gestational ages in several brain 
regions. We observed vascular expansion at 125 days of gestation. The total number of blood vessels 
appeared significantly increased in the white matter regions at term gestation compared to the earlier 
gestational ages regardless of growth restriction. The percentage of MMP9-positive blood vessels 
differed significantly between the gestational ages in the subcortical white matter of FGR and control 
animals. In the white matter regions, the results showed a trend of increased vascular proliferation in 
FGR and control animals at 115 and 125 days of gestation compared to term gestation.  
Conclusions: These results suggest a peak in vascular expansion at 125 days of gestation in FGR 
and control animals. This leads to increased number of blood vessels at term gestation in the white 
matter regions. 
Key words: fetal growth restriction, ontogeny, cerebrovascular development, neurovascular unit 
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3. Introduction  
Fetal growth restriction (FGR), also known as intrauterine growth restriction (IUGR), is a common 
complication of pregnancy when the fetus fails to gain the endorsed growth potential (1). FGR 
affects up to 3-9 % of pregnancies in high-income countries (2). A newborn with an estimated fetal 
weight below the 10th percentile for their sex and gestational age, along with altered placental 
perfusion during pregnancy, is typically diagnosed with FGR (3). Nevertheless, there is no 
internationally recognized definition to this phenomenon (2). 
 
3.1. Background 
FGR is sometimes defined solely based on birth weight (1). Defining FGR by this way creates 
confusion between FGR and a condition named small for gestational age (SGA), and these terms are 
sometimes used synonymously (4). However, because of potentially different aetiologies and 
postnatal outcomes, these two conditions should be distinguished (1). SGA simply refers to a low 
birth weight (4). It may be caused by a variety of constitutional and physiological causes, and is not 
always associated with a pathological outcome (4). This subgroup of small fetuses does not present 
umbilical cord Doppler signs associated with hemodynamic redistribution, histological or 
biochemical signs of placental disease or higher risk of preeclampsia (3). “True” FGR refers to small 
fetuses with a higher risk for fetal in utero deterioration, stillbirth, neonatal death, perinatal 
morbidity, cerebral palsy (CP), and adult diseases, compared to fetuses appropriate for gestational 
age (AGA)  (3, 4). FGR can be differentiated from SGA by Doppler cerebroplacental ratio 
(calculated by dividing the middle cerebral artery pulsatility index by the umbilical artery Doppler 
pulsatility index), by the uterine artery Doppler pulsatility index and by very small estimated fetal 
weight (among fetuses below the 10th centile, those with an estimated fetal weight < p3) (3).  
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3.1.1. Causes of fetal growth restriction 
The various causes for development of FGR are generally categorized as maternal, fetal and 
placental (5). Nevertheless, these aspects may overlap each other (5). Fetal causes include fetal 
infections, chromosomal abnormalities and multiple gestation (1). Maternal factors comprise 
autoimmune, endocrine and cardiovascular diseases, and drug abuse (1, 2). However, the leading 
cause of FGR is placental insufficiency (4). Exact mechanisms that result in progressive deterioration 
in placental function remain unknown (6). In terms of pathophysiology, decreased transfer of oxygen 
and nutrients via placenta to the fetus leads to fetal hypoxemia and reduced fetal growth (7). In 
response to hypoxemia, the fetus may react with an abnormal Doppler cerebroplacental ratio, 
indicative of a brain sparing, a phenomen discussed further in the next section. 
The two different phenotypes of FGR in response to placental insufficiency are early-onset, 
established in the second trimester, and late-onset, established in the third trimester. In early-onset 
FGR, abnormal placental perfusion is caused by villous damage in the vasculature. This leads to 
increased umbilical artery (UA) blood flow resistance, increased UA Doppler index and diminished 
fetal oxygen transfer. In late-onset FGR, villous damage decreases gas and nutrient exchange as well, 
but the effect on vascular resistance is mild, often followed by normal UA Doppler. (8)  
 
3.1.2. Clinical neurodevelopmental outcome of FGR 
What has been observed in growth restricted fetuses is asymmetric fetal growth in which fetal 
cardiac output is redistributed favoring the brain, called brain sparing (9). Brain sparing leads to 
elevated brain:body weight ratio (2). However, this compensatory response is insufficient because 
the brain is not spared in terms of neurodevelopmental outcome (2). The neurological consequences 
of FGR include increased risk for intraventricular-germinal matrix haemorrhage (GM-IVH) (1), 
cerebral palsy (CP) (10), poor prenatal head growth (10), behavioral difficulties (11), cognitive 
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impairment (12), inattention-hyperactivity symptoms (11) and lower school performance (11, 12), 
compared to appropriately grown children. In addition to the neurological outcomes, FGR is linked 
to an overall increased risk for perinatal mortality and morbidity, respiratory difficulties, 
polycythemia, hypoglycaemia and hypothermia (1).   
The clinical outcome following FGR is confounded by its timing and often co-existing prematurity 
(2). When FGR is combined with preterm birth, the risk of cerebral palsy is increased, compared to 
FGR infants delivered at full-term (13). Arduini et al (14) reported that early-onset FGR fetuses 
showed delay in behavioural state transitions, i.e time intervals between two different behavioural 
states, compared to AGA fetuses (14). Harvey et al (15) observed that in early-onset FGR, decreased 
head growth was linked to lower scores for the general cognitive index, perceptual performance and 
motor scales (15). Regarding early-onset FGR infants born preterm, fetal cardiovascular compromise 
correlates to deficits in neurodevelopmental outcome (16). In late-onset FGR, reduction in head 
growth is related to decreased perceptional performance, motor ability, cognition, concentration 
ability and short-term memory, followed by poorer school performance (17). 
 
3.1.3. Neuropathology in humans with FGR 
Several outcome studies have focused on the alterations in brain development in FGR fetuses and 
FGR children. Tolsa et al (18) showed that FGR infants born preterm had a reduction in cerebral 
cortical grey matter volume, intracranial volume and total brain tissue volume on magnetic resonance 
imaging (MRI), compared to gestational-age matched, AGA infants. These findings correlated with 
FGR infants showing less mature scores in attention-interaction subdomain of the Assessment of 
Premature Infants’ Behaviour (APIB), measured at term-equivalent age (18). Samuelsen et al (19) 
observed that the cortical growth was diminished and the cell number in the future brain cortex was 
reduced in FGR affected fetuses autopsied at 19-41 weeks’ gestational age (19). Furthermore, Dubois 
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et al (20) reported that premature FGR newborns had more profound reduction of cortical surface in 
relation to sulcation index (the proportion of ventral, lateral and vertex cortical sulci areas according 
to the brain size) compared to premature, AGA newborns (20). 
When it comes to the hippocampus, it has crucial functions for the formation of memory and learning 
(21). It is shown to be vulnerable when exposed to the hypoxia and undernutrition associated with 
FGR because of its sensitivity to metabolic disturbances (22). Lodygensky et al (23) noted that FGR 
infants born preterm showed reduction of grey matter volume in the hippocampus, compared to 
gestational-age matched AGA infants. This structural difference was followed by FGR infants 
demonstrating less mature scores in all subdomains of the APIB at term-equivalent age (23).  
Advances in brain imaging have greatly progressed the assessment of the FGR brain in infants and 
children. In terms of brain connectivity, Eixarch et al (24) described that 1-year-old children exposed 
to FGR had altered connectivity in motor and cortico-striatal-thalamic network on MRI 
examinations, compared to AGA controls. These results correlated specifically with motor scale and 
cognitive and socioemotional scale results, respectively (24). Fischi-Gomez et al (25) showed that 6-
year-old children born moderately premature with additional FGR showed weaker fractional 
anisotropy-weighted structural connectivity of cortico-basal ganglia-thalamo-cortical loop 
connections, compared to AGA controls born moderately premature. These findings were associated 
with poorer socio-cognitive performance in FGR children (25).  
The risk of cerebral white matter injuries is increased in FGR (26, 27). Infants with periventricular 
white matter injury (PWMI) have immature, poorly perfused cerebral blood vessels (28), implying 
that vascular supply correlates with white matter injury. Late preterm (34-37 weeks) FGR infants 
have been shown to have increased incidence of GM-IVH, compared to AGA preterm infants (29). 
Perinatal brain is most susceptible to hypoxic-ischemic periventricular white matter injury (PWMI), 
leading to cerebral palsy, at 23-32 weeks of gestation (30). Late oligodendrocyte progenitor cells are 
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potential targets for ischemic brain injury, since myelination is disrupted in PWMI (30). For these 
reasons, this study focused on cerebrovascular development in the subcortical and periventricular 
white matter and the subventricular zone (germinal matrix) in FGR and control individuals in late 
gestation. FGR was induced at the gestational age that preceded myelination and coincided with 
vulnerability for white matter injury. The experimental design is described in detail in section 4.1. 
 
3.1.4. Neuropathology in animal models 
There are several animal models that have been established, which demonstrate how FGR affects 
brain structure and development. Basilious et al (31) reviewed the physiological and neurological 
outcomes of FGR induced by uterine artery ligation in animal models. In rats, mice and guinea pigs, 
FGR leads to an overall reduction in body weight. Nonetheless, the reduced body weight is not 
associated with proportional reduction in brain weight in either rats or guinea pigs. Thus, these 
studies suggest relative brain sparing, similar to that observed in humans with brain sparing (31). 
With regard to neuron density, FGR leads to neuronal cell loss and loss of the stratified structure in 
the cerebral parietal cortex in rats, suggesting abnormal neuronal migration (32). Degenerating axons 
and neuronal cell bodies are present in the hippocampus, external capsule, entorhinal cortices, 
cingulate cortex white matter and corpus callosum in a rat model (33). Hypoxia-ischemia induced 
astrogliosis can be detected in the cerebral white matter in FGR guinea pigs (34) and in the 
hippocampus, entorhinal and cingulate cortices in FGR rats (33). Inflammatory microgliosis appears 
in cerebral and cerebellar white matter in FGR guinea pigs (34) and in the cingulate white matter in 
rats (35).  
Myelination plays an essential role in neural maturation and function. FGR guinea pig fetuses have 
reduced number of myelinating oligodendrocytes in the cerebral cortex and cerebellum, but this 
deficit does not persist in young adulthood (34). FGR rat pups show a decreased number of  pre-
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oligodendrocytes and a subsequent delay in myelination (35). In terms of white matter, FGR leads to 
white matter hypomyelination and axonal damage in the brains of fetal sheep (36). Tolcos et al (34) 
used a guinea pig model and demonstrated reduced cerebral and cerebellar white matter volume in 
FGR fetuses and 1-week-old neonates. Nonetheless, control levels in the overall cerebral white 
matter volume were reached by 8 weeks of age, with a persisting decreased width of corpus callosum 
in young adult age (34). Even though FGR is related to motor impairment in humans, Delcour et al 
(37) saw no white matter damage in in the primary motor cortex of FGR rats. Instead, FGR group 
had a diminished total neuron and GABAergic interneuron density in the somatosensory cortex. 
Markers indicating apoptosis were increased in several white matter areas (37).  
Appropriate neuronal connectivity is crucial for higher-order cognitive and motor behaviours (38). 
Eixarch et al (39) noted that FGR rabbit pups showed a different brain diffusivity pattern in magnetic 
resonance imaging (MRI) in the grey and white matter of multiple brain regions, compared to 
appropriately grown controls. MRI diffusion findings correlated with observed neurobehavioral 
impairments (39). Regarding the structure of the hippocampus, decreased hippocampal volume at 
birth appeared in a FGR rat model (40). Neuronal density was decreased in the hippocampus of a 
guinea pig model (41). Illa et al (42) demonstrated that FGR rabbits at 70+ postnatal days presented a 
higher degree of anxiety, attention and memory problems than control animals. These are some of 
the cognitive and neuropsychological features described in FGR children (42). 
Regarding the gestational age in which FGR is induced, Rocha et al (43) showed that early-onset 
FGR differs from late-onset FGR in terms of neuropathological outcome in fetal sheep. Early-onset 
FGR led to progressive hypoxia during the first 10 days of placental insufficiency and resulted in 
more severe brain damage compared to late-onset FGR. Neuropathological outcome comprised white 
matter hypomyelination, loss of cortical organization, loss of neuronal integrity in the grey matter, 
and neuroinflammation with reactive astrogliosis. Late-onset FGR resulted in an immediate acute 
fetal hypoxic response after induction of placental insufficiency, followed by chronic hypoxia. 
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Increased apoptosis within the cortex, in the cortical white matter and subventricular zone were 
identified in the late-onset FGR animals. In both late-onset and early-onset FGR groups, 
neuropathological findings included mature oligodendrocyte cell loss and a trend towards increased 
degeneration of cortical neurons, compared to control animals (43) 
 
3.1.5. The cerebral vasculature and the neurovascular unit  
The basic cellular and histological structure forming the interactions between the blood vessels of the 
brain, and the brain parenchyma, are the neurovascular unit (NVU, figure 1) and the blood-brain-
barrier (BBB). The definition of the BBB has varied over the past decades, but the current literature 
on this subject has been reviewed in detail by Hawkings et al (44) and Obermeier et al (45). The 
BBB functions as a selective diffusion barrier at the level of the cerebral microvascular endothelium, 
separating the central nervous system (CNS) brain parenchyma from the peripheral blood circulation. 
The BBB maintains the optimal brain homeostasis by controlling the passage of molecules and ions, 
delivering nutrients and oxygen, and by protecting the brain from toxins and pathogens (44, 45). 
The BBB comprises a single layer of endothelial cells surrounding the circumference of a cerebral 
capillary lumen (44). Compared to endothelial cells in the periphery, endothelial cells of the BBB 
have increased mitochondrial content, lack fenestrations and have minimal pinocytotic activity (44).  
The opposing membranes of the endothelial cells are connected by continuous intercellular tight 
junctions which limit the movement of molecules through the endothelial cell layer, essentially into 
the brain (46). Immune cell infiltration to the healthy CNS is prevented by a low expression of 
endothelial cell leukocyte adhesion molecules (47).  
In order to secure adequately supply of oxygen and nutrients to the brain parenchyma, cerebral blood 
vessels need to build up an appropriate network (48). The neurovascular unit is composed of groups 
of neurons and their associated astrocytes, interacting with smooth muscle cells and endothelial cells 
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on the microvessels, pericytes, microglial cells, and the basement membrane that encloses the 
endothelial cells (44-46). Cells within the NVU work as a complex network (45). They provide 
functional and structural support to the BBB, maintain brain homeostasis and the integrity of the 
BBB (48). As a whole, the NVU regulates cerebral blood flow and provides growth factors that 
contribute to appropriate oxygen and nutrient supply necessary for normal brain development (45, 
48).  
When it comes to pericytes and astrocytes, pericytes share a common basement membrane with 
endothelial cells and regulate BBB permeability, cerebral blood flow and clearance of toxic cellular 
by-products (49). CNS vascular endothelium has increased pericyte coverage compared to peripheral 
tissues (49). Astrocytes perform neurovascular tasks including providing nutrition for neurons, 
buffering extracellular potassium balance, regulating neurotransmitter release, controlling immune 
reaction and forming the BBB (50).  
 
Figure 1  The components of the neurovascular unit. The image used with permission of Dr Margie 
Castillo-Melendez. "Basal membrane" is used synonymously with "basement membrane". 
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With regard to the structure of the basement membrane, it comprises collagen type IV, elastin, 
fibrillin, laminin, fibronectin, cell adhesion molecules, and extracellular matrix and signalling 
proteins (51). The endothelial cells interact with laminin, collagen type IV and other matrix proteins 
which anchor the endothelial cells to the basement membrane (52). Matrix proteins boost the 
expression of endothelial tight junction proteins, making the basement membrane an important 
player in maintaining the tight junctions (52). Cell-matrix interactions are involved in intracellular 
signalling pathways (52). In pathological conditions, for example glioblastoma multiforme, changes 
in the molecular composition of the endothelial tight junctions and the basement membrane can be 
observed (53). Schöller et al (54) found that the microvascular basement membrane damage 
correlates with BBB disruption. This suggests that the basement membrane restricts extravasation of 
proteins into the brain parenchyma (54).  
 
3.1.6. Cerebrovascular development at the molecular level 
Brain vascularisation during embryogenetic, fetal and newborn period is a complex process that 
involves a large number of cells and growth factors (55). It begins with vasculogenesis in which 
endothelial progenitor cells (EPC) differentiate into endothelial cells forming a primitive capillary 
network (55). Vasculogenesis is followed by angiogenesis which refers to formation of blood vessels 
by proliferation, migration and remodelling of endothelial cells into avascular tissue and sprouting of 
capillaries from pre-existing vessel networks (55).  
In angiogenesis, matrix metalloproteinases (MMPs) are a family of proteins that control degradation 
of the extracellular matrix of the basement membrane (56). Endothelial cell migration and 
proliferation is then accomplished by activation of chemoattractants and mitogens (56). Next, tube 
formation takes place, followed by reconstitution of a basement membrane (56). Korzhevskii et al 
(57) showed that in the developing human telencephalon, the first intracerebral blood vessels are 
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formed from 7 weeks of gestation. They observed that primitive capillary network appears first, 
followed by formation of the basement membrane (57).  
Endoglin is a transmembrane glycoprotein that can be used as an endothelial cell marker (58). It is 
expressed in proliferating endothelial cells in the blood vessel endothelium, and its expression is 
increased during angiogenesis (58). Moving on to consider laminin, it is a non-collagenous 
glycoprotein that consists of two polypeptide chains joined by disulphide bonds (59). Its expression 
indicates early vascular development (60). Together with collagen type IV, laminin supports the 
structure of the basement membrane (61). Deposition of laminin facilitates maturation of capillaries 
and inhibits cell migration and proliferation (56). In the more mature and adult brain, laminin is only 
expressed in the basement membrane (62). However, during brain development, laminin is expressed 
by precursors of neurons and glial cells, suggesting laminin may play a role in neuronal migration 
(62). In response to brain injury, laminin expression is induced in mature astrocytes (63). Milner et al 
(64) found that maturation of blood vessels was associated with up-regulation of laminin expression 
in the developing mouse central nervous system (64).  
In terms of cell proliferation, Ki67 is a protein that appears during all active phases of the cell cycle 
(65). During interphase, it is expressed solely within the nucleus, and during mitosis it is located on 
the surface of the chromosomes (65). It is absent in resting cells and can therefore be used as a 
proliferation biomarker that labels cell growth in a cell population (65). It is also used as a prognostic 
biomarker and to predict treatment response in solid tumours (66). In response to injury, Ki67 is 
expressed in proliferating cells in the vasculature (67).  
A significant protein in terms of vascular development is vascular endothelial growth factor (VEGF), 
a disulphide-linked dimeric glycoprotein that regulates endothelial cell growth and proliferation, 
angiogenesis and vascular permeability (68). Physiological and pathological angiogenesis is 
stimulated by VEGF in a dose-dependent manner (69). VEGF promotes axonal outgrowth, Schwann 
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cell proliferation, and nerve cell and Schwann cell survival in the superior cervical ganglia and dorsal 
root ganglia in an adult mouse model (70). During physiologic conditions in the brain, VEGF is 
mainly expressed by choroid plexus epithelial cells, astrocytes and microglia (71). VEGF may be 
involved in ingrowth of capillaries from the perineural vascular plexus (72).   
 
3.1.7. Angiogenic response to hypoxia-ischemia 
Hypoxia-ischemia affects the cerebral vasculature in several ways. Focal cerebral ischemia induces 
an immediate breakdown of the primary endothelial cell permeability barrier, expression of matrix 
metalloproteinases, and appearance of receptors associated with angiogenesis and neovascularization 
(new blood vessel formation) in cerebral microvessels (73). Krupinski et al (74) observed angiogenic 
activity in human postmortem brain tissue after stroke. The number of microvessels was higher in 
infarcted brain tissue compared to the contralateral normal hemisphere, and increased number of 
blood vessels correlated with longer survival. Infarcted hemispheres had lower number of 
microvessels filled with blood cells, but the number of empty ones was higher (74). 
Baburamani et al (75) demonstrated that a 10-minute, severe, acute hypoxic insult induced by 
umbilical cord occlusion led to decreased vascular density in caudate nucleus in late-gestation fetal 
sheep. Furthermore, the number of blood vessels £ 10µm of perimeter was relatively decreased and 
the number of blood vessels £ 100µm of perimeter was relatively increased in the periventricular and 
subcortical white matter, compared to control animals not exposed to hypoxia. This enlargement of 
blood vessels remained in the white matter for up to 48 hours following the brief hypoxic insult (75). 
Nonetheless, Castillo-Melendez et al (48) found no significant differences in vascular morphology in 
the white matter of full-gestation fetal sheep exposed to chronic hypoxia in utero (FGR animals) 
compared to gestational-age matched, appropriately grown control animals. Instead, they showed 
reduced blood vessel density in the subcortical and periventricular white matter and the 
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subventricular zone in FGR animals. They reported also that pericyte coverage of the blood vessels 
and the number of peri-vascular astrocytes in the white matter regions examined were lower in the 
FGR group (48). 
Apart from angiogenesis, neovascularization after focal cerebral ischemia can also occur via de novo 
formation of blood vessels, vasculogenesis (55). Endothelial progenitor cells (EPC) migrate to the 
site of the injury, differentiate and release growth factors that contribute to vessel formation (55). 
Zhang et al (76) showed with an adult mouse model that bone-marrow derived EPC promoted to 
neovascularization in the brain tissue damaged by ischemia (76).  
Regarding the link between hypoxia-ischemia and MMP9, Zalewska et al (77) used a gerbil model 
and demonstrated that transient cerebral ischemia led to up-regulation of MMP9 in dorsal parts of 
hippocampus. This was followed by degradation of laminin, substrate of the MMP9, in the CA1 
region of the hippocampus. They suggest that the MMP pathway may be involved in delayed 
neuronal death after short-term global ischemia (77). Reviewed by Rosenberg et al (78), an ischemic 
insult in the brain activates MMP2, leading to disruption of the BBB. This BBB injury follows a 
biphasic pattern with a second, more severe disruption 24-48 hours later, associated with brain 
oedema and haemorrhage. The second phase correlates with increased levels of MMP9. In 
conclusion, the author suggests that hypoxia-ischemia leads to activation of the MMPs which results 
in degradation of the basement membrane and increases the risk of haemorrhage (78).  
MMP9 knock-out, adult mice subjected to focal cerebral ischemia are shown to have reduced 
ischemic lesion volumes (79), reduced BBB disruption (80) and decreased ischemic degradation of 
the MMP9 substrate, myelin basic protein (80), compared to wild-type mice. Svedin et al (81) 
studied MMP9 knock-out neonatal mice exposed to hypoxia-ischemia and reported that MMP9 
deficiency reduced loss of cerebral tissue and white matter components, delayed and reduced 
opening of the BBB and decreased inflammation, compared to wild-type animals. (81). 
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VEGF has been widely studied in the context of hypoxia-ischemia. Reviewed by Hermann and 
Zechariah (71), hypoxia-ischemia in the brain result in VEGF expression in neurons, microvascular 
smooth muscle cells, pericytes and leucocytes, and the expression is up-regulated in glial cells (71). 
Local VEGF administration after stroke contributes to reduced ischemic brain damage and 
neurologic recovery with sensorimotor, coordination, and cognitive improvements (71). 
Nevertheless, acute systemic VEGF administration after stroke leads to increased brain injury, 
haemorrhagic transformation, microvascular injury, inflammation, permeability of the BBB and 
albumin extravasation (71). Schoch et al (82) observed that hypoxia was associated with increased 
expression of VEGF and increased vascular permeability in mice brains. Furthermore, levels of 
VEGF correlated with the severity of the hypoxic insult. Hypoxia-induced effect on vascular 
permeability disappeared by VEGF inhibition, suggesting that vascular leakage following cerebral 
hypoxia is associated with VEGF (82). On the other hand, distribution of VEGF and the vascular 
proliferation were decreased in the full-term lamb brain exposed to chronic hypoxia in utero (48).  
When it comes to the impact of hypoxia-ischemia on BBB stability, hypoxia with reoxygenation is 
shown to modify tight junction protein expression in cerebral blood vessels in adult rats, suggesting 
that this reorganization leads to altered paracellular diffusion in the BBB (83). The first cells that 
react to brain hypoxia are pericytes, starting to migrate from their original location during the first 2 
hours of hypoxia (84). Ferrari et al (85) studied neonatal hypoxia-ischemia using a rat pup model. 
They observed an increased BBB permeability 1 to 7 days and cerebral oedema 1 to 21 days after the 
hypoxic-ischemic insult (85). While Ek et al (86) found that hypoxia-ischemia in neonatal mice 
indicated that the BBB opening occurred early and was normalized by 3 days after insult (86). 
Castillo-Melendez et al (48) observed albumin extravasation in the white matter of FGR lamb brains, 
indicating reduced integrity of the BBB. They also noted increased number of microbleeds in the 
subventricular zone of FGR animals, compared to appropriately grown controls (48). 
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3.1.8. Summary  
In summary, it is well established in adult post mortem human studies and in animal models of 
hypoxia-ischemia that the BBB and NVU become compromised. This is mediated via an acute 
upregulation of VEGF, followed by MMP activation and breakdown of the basement membrane. 
Subsequently, the integrity of the brain is altered, thereby allowing peripheral cells more easy access 
into the brain. What is not known so far is what happens in the developing brain, and in particular, 
what happens in response to a chronic hypoxic insult, as occurs with FGR. To examine this, the use 
of an appropriate and relevant animal model that has been exposed to intrauterine hypoxia, such as to 
mimic placental insufficiency, is needed. Understanding cerebral vascular changes that take place in 
relation to the FGR during well identified periods of brain development, during which the fetal brain 
is particularly susceptible to injury, may allow us to identify potential neuroprotective targets for 
FGR infants.   
 
3.2. Research question 
We hypothesize that placental insufficiency induces a compensatory, angiogenic response in the 
brains of FGR fetal sheep in early pregnancy. This angiogenetic response is characterized by 
increased VEGF immunoreactivity, increased MMP9 and Ki67 expression in the cerebral blood 
vessels and increased total number of cerebral blood vessels in FGR animals, compared to control 
animals. We want to determine whether this angiogenetic response to reduced placental blood flow is 
maintained in FGR animals as the hypoxia becomes chronic when the pregnancy approaches full 
term.  
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3.2.1. Specific aims:  
•   In this experimental ontogeny study, we aim to examine distribution of laminin (a major 
component of the basement membrane), VEGF (one of the most important pro-angiogenic 
mediators), MMP-9 (degrades the extracellular matrix and promotes angiogenesis), endoglin 
(expressed on proliferating endothelial cells) and Ki67 (cellular marker for proliferation) in the 
developing, growth-restricted ovine brains and compare the distribution to appropriately grown, 
gestational-age matched control animals. 
•   We aim to compare the distribution of the expression of these proteins in the subcortical and 
periventricular white matter and the subventricular zone following the induction of placental 
insufficiency (single umbilical artery ligation) and as the pregnancy progresses to full term using 
an ovine model of FGR and immunohistochemistry. 
 
4. Material and Methods 
The animal work and tissue collection described below was previously performed at Monash 
Medical Centre except for cutting the tissue. The tissue came from three different studies undertaken 
2012, 2014 and 2017 (36, 43, 87). My part in this project was to examine the effect of placental 
insufficiency on the cerebral vasculature by staining previously collected brain sections with specific 
immunohistochemistric markers, conducting light microscopy or image viewing software image 
collection, and analysing the resulting data which is presented on this report.  
 
4.1. Experimental design  
We used three cohorts of Border-Leicester cross Merino pregnant ewes. The tissue material came 
from their fetuses which represented three different gestational ages (GA, in days): 115 GA (early 
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preterm, corresponds to ~31 weeks in humans), 125 GA (late-preterm, corresponds to ~34 weeks in 
humans) and full term (fig 2). Each experimental group had its gestational-age matched, 
appropriately grown control group. Experimental groups and control groups comprised seven 
animals (n=7). The gestational age at full term delivery ranged 145 ± 0.9 days in the control group 
and 144 ± 0.6 days in the FGR group, expressed as mean ± SEM (36). The full-term groups are 
referred to as 145 GA throughout this thesis.  
In the 115 and 125 GA groups, we used twin-bearing ewes. One of the twins of the same ewe was 
growth-restricted and the other one used as a control. In the 145 GA group, we used a growth 
restricted group and a control group of lambs delivered after singleton, full-term pregnancy. 
Altogether, there were six animal groups in this project.  
 
4.2. Surgical procedure and animal maintenance  
In each of the FGR groups, fetal growth restriction leading to placental insufficiency was surgically 
induced at 105 GA (fig 2). The surgical procedures have been described in detail in the previous 
publications that used the same animal cohorts (36, 43, 87). In summary, placental insufficiency was 
induced by single umbilical artery ligation (SUAL, fig 3) under anaesthesia. Two silk ligatures were 
placed tightly around one of the umbilical arteries. The fetus was then returned to the uterus. In the 
groups of 115 GA and 125 GA, the ewes and the fetuses were euthanized at these gestational ages, 
via a maternal overdose of intravenous pentobarbitone. In the group of 145 GA, the ewes gave birth 
to their fetuses, and the lambs were euthanized 24 hours postpartum in the same manner as the 
groups of the two other gestational ages. We chose to induce placental insufficiency specifically at 
105 GA because that precedes the myelination process (fig 2) and corresponds to the gestational age 
with the highest risk for clinical white matter injury in humans (88).   















circulation X SUAL 
X X X X X 
X X X X X 
Figure 3  In single umbilical artery ligation (SUAL), one umbilical artery is fully ligated. 
This causes infarction/death of approximately half of the placental cotyledons, leading to 
placental insufficiency. This induces progressive fetal hypoxia and hypoglycaemia.     
Figure 2 Fetal gestation in humans and sheep. The gestational ages in humans are shown in the purple arrow (weeks), 
and the corresponding gestational ages in sheep are shown in the blue arrow (days). Late pre-term fetuses have an 
increased risk of intraventricular hemorrhage (IVH). The human brain is most susceptible for white matter injury at 23-
32 weeks of gestation, the developmental window preceding myelination. In this study, placental insufficiency with 
subsequent fetal growth restriction was induced at 105 days of gestation (105 GA, ~28 weeks of gestation in humans) by 
single umbilical artery ligation. Growth restricted and control fetuses studied were of three gestational ages: 115 days 
(115 GA, ~31 weeks in humans), 125 days (125 GA, ~34 weeks in humans) and full-term lambs (145-147 GA). The image 
adapted with permission of Dr Margie Castillo-Melendez. 
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It has previously been shown that placental insufficiency induced by single umbilical artery ligation 
at 105 GA leads to fetal hypoxemia from day 1 following the surgery, based on fetal arterial blood 
gas samples (43). In the animals used in this project, the body weights were reduced in FGR 
individuals compared to controls at all ages (figure 4), but the differences were statistically 
significant only at 115 and at 145 GA (table 1). However, when the 125 GA animal cohort was 
previously studied and a higher number of animals was included in the study, there was a statistically 
significant difference in body weights between FGR and control animals at this gestational age as 
well (43). 
Table 1 Body weights of control lambs and FGR lambs 
 
Body weight, kg 
Control 115 days 1.99±0.127 
FGR 115 days 1.59±0.124* 
Control 125 days 3.34±0.254 
FGR 125 days 2.70±0.149 
Control 145 days 4.68±0.227 
FGR 145 days 3.37±0.523* 
FGR = fetal growth restriction. Kg = kilograms. Data presented as means 
± SEM. *p <0.05: significantly different from control of the corresponding 
gestational age. Control 115 days = control group at 115 days of gestation. 
FGR 115 days = growth restricted group at 115 days of gestation. Control 
125 days = control group at 125 days of gestation. FGR 125 days = growth 
restricted group at 125 days of gestation. Control 145 days = control group 
at term (~ 145 days) gestation. FGR 145 days = growth restricted group at term (~ 145 days) gestation. N= 7. 
In previous studies with these animal cohorts, it has been shown that there was no significant 
difference in brain weight between the FGR animals and the control animals in the groups of 125 and 
145 GA (36, 43). In the cohorts of 115 and 145 GA, there was a significant increase in brain/body 
weight ratio in FGR individuals compared to control individuals (36, 87). Decrease in body weight 
without corresponding decrease in brain weight suggests asymmetric growth restriction and brain 
sparing. Nevertheless, I was not able to obtain the brain weights for the particular animals I used in 
my project, so I was unable to determine the brain/body ratios.   
Figure 4 A growth restricted lamb at term (left) and 
an appropriately grown lamb of the corresponding 
gestational age. 
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4.3. Tissue preparation 
The brains were collected, weighed and divided into left and right hemisphere. We used the right 
hemisphere in my study, which was cut into 0.5 cm coronal blocks and fixed in 10 % buffered 
formalin or 4 % buffered paraformaldehyde. Three days later, the blocks were fixed in paraffin (fig 
5a). During the first weeks of my project, a research assistant cut the blocks into 10 µm coronal 
sections (fig 5b) at the level of the subventricular zone (SVZ, also known as the germinal matrix). 







We chose to study these particular brain areas and focused on the vascular development because 
premature infants in combination with FGR suffer from high rates of haemorrhages within the 
subventricular zone (SVZ) germinal matrix of the brain (89, 90). Furthermore, the risk of white 
matter injuries is increased in FGR (26, 91). 
  
Figure 5a-b. The blocks of brain tissue were embedded in paraffin and cut into 10 µm coronal sections.  
5a 5b 
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4.4. Immunohistochemistry 
We used immunohistochemistry (IHC) in this study because it allows us to visualize the antigen and 
identify its localisation and distribution in the tissue (92). A total of five different protocols of 
indirect IHC were used in this study: single-label IHC for laminin, MMP9, VEGF and Ki67 and a 
double-label fluorescence IHC for Ki67 and endoglin. Seven animals per group (n=7) and two 
sections per animal were used for the single-label stainings, making a total of 42 animals and 84 
sections. Five animals per group (n=5) were used for the double label fluorescence, making a total of 
30 animals and 60 sections. 
In every staining, hydrogen peroxide and DAKO protein free blocking solution were used to reduce 
non-specific background staining. The sections were incubated with a primary antibody the first day, 
and with a secondary antibody the following day. In the single-label protocols, the staining was 
visualized with streptavidin-HRP (horseradish peroxidase) and 3,3’ diaminobenzidine (DAB) 
complex. The sections stained for MMP9 and Ki67 were counterstained with cresyl violet. The 
protocol for single-label, indirect VEGF IHC was performed with practice sections with an intention 
of later running it on the same animals as I used for the rest of my study. Before completing the 
protocol for MMP9, optimisation of the protocol was carried out as MMP9 was an IHC marker not 
previously used by my research group.  
All detailed protocols for the five different IHC stainings are found in the appendix of this 
thesis.  
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4.5. Tissue Microscopy and Imaging  
The stained sections were imaged with a light microscope or a digital image viewing software. The 
imaging procedures for each staining are described in detail below.  
4.5.1. Laminin imaging 
The sections stained with laminin were scanned and images were captured at x50 magnification with 
an image tool Aperio ImageScope [v12.3.2.8013] using a personal computer. Three random fields of 
view (figure 6) per brain region (subventricular zone, periventricular white matter, subventricular 
white matter) in each section were taken. 
  
Figure 6. A coronal sections of an ovine brain stained with laminin immunohistochemistry with the 
target regions imaged in this study. The MMP9 staining and the Ki67 staining were imaged in the 
same manner. 3 or 4 fields of view per target regions were imaged in each sections. SCWM = 
subcortical white matter. PVWM = periventricular white matter. SVZ = subventricular zone 
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4.5.2 MMP9 and Ki67 imaging  
Images of the MMP9 and Ki67 staining were taken under a light microscope (Olympus BX41; 
DP25camera, Olympus, Japan) at x400 magnification. 4 random fields of view per brain region 
(subventricular zone, periventricular white matter, subventricular white matter) in each section were 
taken. 
 
5. Data collection procedures  
The images for each staining were quantified. The quantification processes are described in detail 
below. The data from the images was then statistically analyzed, described in detail below. 
 
5.1 Image analysis 
The images from the sections stained with laminin were used to assess blood vessel number and 
morphology. The images stained with MMP9 were used to measure extracellular matrix degradation 
and promotion of angiogenesis, and the images stained with Ki67 to evaluate endothelial cell 
proliferation.  
 
5.1.1. Assessment of blood vessel number and morphology (laminin)  
All measurements for the sections stained with laminin were carried out with Metamorph Offline 
(v7.7, Molecular Devices, USA) software. All positive staining that occupied less than 20 pixels was 
excluded from the analysis. All the data was expressed in pixels and converted to micrometers. The 
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software gave us the area, perimeter, length and breadth for each individual vessel in every image 
(figure 7). This was our raw data. From the raw data, the values for all the blood vessels in each 
image were averaged, and we ended up with an average value for each parameter in each image. The 
total number of vessels for each image was calculated by the software. The averages were sorted on 
Excel-sheets by groups, by regions, by animal numbers and by parameters. Images for each animal 
were averaged so that each animal ended up with one value for vessel area, perimeter, length, breadth 
and total number of blood vessels per region. 
 
5.1.2. Quantification of extracellular matrix degradation and cell proliferation 
For the MMP9 and Ki67-staining, the number of MMP9 or Ki67-positive blood vessels were 
manually counted by Dr Castillo-Melendez blinded to the experimental groups. A total of 4 fields of 
view per brain region in 2 sections per animal were manually counted using the cell counter plugin 
on the Fiji software (ImageJ). The total number of blood vessels in a field of view was also counted 
by her and the number of blood vessels that were MMP9 or Ki67-positive was divided by the total 
Figure 7 The morphology of the blood vessels was assessed by staining them with laminin 
immunohistochemistry. The length, perimeter, breadth and area of each blood vessel were calculated 
with Metamorph Offline software. The values for all the vessels in a field of view were then averaged, 
resulting in one value per parameter for each field of view. Magnification x100.  
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number of blood vessels in a field of view (figure 8-9). We ended up with the percentage of MMP9 
or Ki67-positive blood vessels of all the blood vessels in a field of view. From this raw data, the 














Figure 8 An MMP9-positive blood vessel is marked with a red arrow. The number of MMP9-positive blood 
vessels was manually counted and divided by the total number of blood vessels in a field of view Magnification 
x400.  
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5.2. Statistical analysis 
Visual illustrations and statistical analysis were carried out with Graphpad Prism version 7.0d. Data 
for each parameter in the brain regions examined was statistically analysed with two-way analysis of 
variance (ANOVA, comparison between the gestational ages) and post-hoc multiple comparisons 
test with Bonferroni correction (comparison between FGR and control animals). Prior to running 
ANOVA, distribution of each data set was analysed with Shapiro-Wilk normality test. The 
significance was set at p<0.05.  
 
Figure 9 A Ki67-positive blood vessel is marked with a red arrow. The number of Ki67-positive blood vessels was manually 
counted and divided by the total number of blood vessels in a field of view. Magnification x400. 
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6. Ethics 
The surgical and experimental procedures undertaken in this project were approved by the Monash 
Medical Centre Animal Ethics Committee, using guidelines established by the National Health and 
Medical Research Council of Australia. We wanted to study cerebral vascular adaptations and 
angiogenetic processes associated with FGR during fetal development. Because of the complexity of 
this research question and the confounding factors such as prematurity, there is no other way of 
pursuing this study than using a large animal model with sufficient fetal size and gestational length.  
 
7. Results 
The results are presented separately for each staining as images, graphs and statistical results. All 
data is shown as mean ± standard error of the mean (SEM). 
 
7.1 VEGF immunohistochemistry  
This protocol was already established in our laboratory but was performed unsuccessfully due to a 
change on the antibody clone by the supplier. No staining could be detected using this particular 
antibody on our test sections, so we chose to not conduct a full run of this particular stain on a larger 
set of sections.   
 
7.2 Double label fluorescence immunohistochemistry 
When the protocol for double label fluorescence for Ki67 and endoglin was completed, and it was 
time to take pictures with the fluorescence microscope, we found that the staining was too faint due 
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to decay of fluorescence signal of the Alexa fluorescent secondary antibodies. No good-quality 
pictures could be taken, thereby we chose to leave this staining out of this project. Nonetheless, we 
wanted to determine cell proliferation, so we chose to perform a protocol of indirect, single-label 
Ki67 IHC instead. 
 
7.3 Assessment of blood vessel number and morphology 
Representative images of the brain sections stained with laminin immunohistochemistry, sorted by 
brain regions and by groups, are presented in figure 10. A reduction of laminin staining and 
decreased blood vessel length and breadth appear in both control and FGR groups at 145 GA 
compared to 115 and 125 GA groups. However, quantification of the staining was not completely 
consistent with this observation based on image data. Results from the quantification are explained in 
detail below (figures 11-15).  
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Figure  10. Brain sections stained with laminin immunohistochemistry, x200 magnification. PVWM = periventricular white matter. 
SCWM = subcortical white matter. SVZ = subventricular zone. 115, 125 and 145 are the gestational ages in days. FGR (fetal growth 
restriction) represents the groups exposed to placental insufficiency, control represents the appropriately grown control groups.  












The number of blood vessels in each image was significantly different between the gestational ages 
in both FGR and control animals in all of the brain regions studied (fig 11a-c). In the white matter 
regions, there appeared to be an increase in the number of vessels in both the FGR group and the 
control group at 145 GA, compared to the two earlier gestational ages (fig 11a-b). In the 
subventricular zone, the number of blood vessels appeared to be decreased at later gestational ages 
compared to 115 GA in FGR and control animals (fig 11c). No statistically significant differences 
between the FGR group and the control group were observed in any of the brain regions or 
gestational ages studied (fig 11a-c). 
  
Figure 11a-c. Blood vessel number in a field of view at different gestational ages. PFGR = P-value when the FGR group and the 
control group of the corresponding gestational ages were compared. Ptime = P-value when the gestational ages in the same region 
were compared. NS = non-significant.  Data presented as means ± SEM, significance set at P <0.05. Nb=number. PVWM = 
periventricular white matter. SCWM = subcortical white matter. SVZ = subventricular zone N=6-7 animals/group. 
11a 11b 
11c 
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There were statistically significant differences in the blood vessel area between the gestational ages 
in all the brain regions studied in FGR and control animals (fig 12a-c). The blood vessel area 
appeared increased at 125 GA compared to 115 and 145 GA in all the brain regions studied (fig 12a-
c). The differences between FGR and control groups did not reach statistical significance in any of 
the brain regions at any of the gestational ages studied (fig 12a-c).  
12a 12b 
12c 
Figure 12a-c. Blood vessel area at different gestational ages in the brain regions studied. PFGR = P-value 
when the FGR group and the control group of the corresponding gestational ages were compared. Ptime = P-
value when the gestational ages in the same region were compared. NS = non-significant. Data presented as 
means ± SEM, significance set at P <0.05. PVWM = periventricular white matter. SCWM = subcortical 
white matter.  SVZ = subventricular zone. N =6-7 animals/group.  
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Blood vessel perimeter was significantly different between the gestational ages in the subcortical 
white matter and the subventricular zone in FGR and control animals (fig 13b-c). In these regions, 
the perimeter appeared to be increased at 125 GA, compared to 115 and 145 GA. There were no 
statistically significant differences in vessel perimeter between the FGR group and the control group 
in any of the brain regions at any of the gestational ages studied (fig 13a-c).  
  
13a 
Figure 13a-c. Blood vessel perimeter in the brain regions studied.  PFGR = P-value when the FGR group 
and the control group of the corresponding gestational ages were compared. Ptime = P-value when the 
gestational ages in the same region were compared. NS = non-significant. Data presented as means ± 
SEM, significance set at P <0.05. PVWM = periventricular white matter. SCWM = subcortical white 







































Blood vessel length was significantly different between the gestational ages in the subcortical white 
matter and the subventricular zone in FGR and control animals (fig 14b-c). In these regions, the 
blood vessel length appeared increased at 125 GA, compared to the two other gestational ages. There 
were no statistically significant differences between the FGR group and the control group in any of 
the brain regions at any of the gestational ages studied (figure 14a-c).  
  
Figure 14a-c.  Blood vessel length at different gestational ages in the brain regions studied. PFGR = P-
value when the FGR group and the control group of the corresponding gestational ages were compared. 
Ptime = P-value when the gestational ages in the same region were compared. NS = non-significant.  
Data presented as means ± SEM, significance set at P <0.05. PVWM = periventricular white matter. 
SCWM = subcortical white matter. SVZ = subventricular zone N=6-7 animals/group.  
14a 14b 
14c 
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Blood vessel breadth differed significantly between the gestational ages in the subcortical white 
matter and the subventricular zone in FGR and control animals (fig 15b-c). In the subcortical white 
matter, vessel breadth appeared increased at 125 GA, compared to the two other gestational ages (fig 
15b). In the subventricular zone, vessel breadth appeared decreased at 145 GA, compared to 115 and 
125 GA (fig 15c). No differences between the FGR group and the control group reached statistical 
significance in any of the brain regions at any of the gestational ages studied (15a-c).   
Figure 15a-c. Blood vessel breadth at different gestational ages in the brain regions studied. PFGR = P-value when the FGR 
group and the control group of the corresponding gestational ages were compared. Ptime = P-value when the gestational ages 
in the same region were compared. NS = non-significant.  Data presented as means ± SEM, significance set at P <0.05. 
PVWM = periventricular white matter. SCWM = subcortical white matter. SVZ = subventricular zoneN= 6-7 animals/group. 
15a 15b 
15c 
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7.4 Evaluation of extracellular matrix degradation with MMP9-staining 
Representative images of the MMP9-staining are presented in figure 16. MMP9 was mainly located 
around the blood vessels. Visualization of the blood vessels and MMP9 requires individual 
adjustments in the light contrast and color exposure using Fiji software and are therefore difficult to 
see in these images. No clear trends in the distribution of MMP9 could be observed in these images. 
  
Figure 16. Brain sections stained with matrix metalloproteinase 9 (MMP9) immunohistochemistry, x400 magnification. PVWM = 
periventricular white matter. SCWM = subcortical white matter. SVZ = subventricular zone. 115, 125 and 145 are the gestational 
ages in days. FGR (fetal growth restriction) represents the groups exposed to placental insufficiency, control represents the 
appropriately grown control groups. 
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In the subcortical white matter, there was a statistically significant difference in the percentage of 
MMP9-positive blood vessels out of the total number of blood vessels between the gestational ages 
in FGR and control animals (fig 17b). The percentage MMP9-positive blood vessels appeared to 
decrease as a function of the gestational age in this region. In the subventricular zone, there was a 
statistically significant difference between the FGR group and the control group at 145 GA (fig 17c). 
In the periventricular white matter, there were no statistically significant differences between the 
gestational ages or between the FGR groups and the control groups (fig 17a)  
Figure 17a-c. Percentage of MMP9-positive blood vessels out of the total number of blood vessels in a field of view. PFGR is the P-value 
when the FGR group was compared to the control group. Ptime is the P-value when the different gestational ages in the same region were 
compared. PFGR-115, PFGR-125 and PFGR,145  are the p-values when the FGR group and the control group at 115, 125 and 145  days of 
gestation, respectively,  were compared. NS = non-significant. Data presented as means ± SEM, significance set at P <0.05. * : a 
statistically significant difference between the FGR group and the control group. BV=blood vessel. PVWM = periventricular white 
matter. SCWM = subcortical white matter. SVZ = subventricular zone. N=5-7 animals/group. 
17a 17b 
17c 
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7.5 Measurement of endothelial cell proliferation with Ki67 staining 
Representative images of the Ki67-staining are presented in figure 18. In the 125 GA groups, a trend 
of higher intensity of Ki67-staining could be observed in the subventricular zone compared to the 
other regions. Apart from that, no clear trends could be observed based on the image data.  
Figure 18. Brain sections stained with Ki67 immunohistochemistry, x400 magnification. PVWM = periventricular white matter. SCWM = 
subcortical white matter. SVZ = subventricular zone. 115, 125 and 145 are the gestational ages in days. FGR (fetal growth restriction)  
represents the groups exposed to placental insufficiency, control represents the appropriately grown control groups.  
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There were no statistically significant differences in the percentage of Ki67-positive blood vessels 
out of the total number of blood vessels between the gestational ages or between the FGR group and 
the control group in any of the brain regions at any of the gestational ages studied (fig 19a-c). In the 
subventricular zone, there was a trend of increase in the percentage of Ki67-positive blood vessels at 
125 GA in both the FGR group and the control group, compared to 115 GA and 145 GA (p-value 
0.1677 between the gestational ages, fig 19c). We could also observe a trend of increase in the 
percentage of Ki67-positive blood vessels in both FGR group and the control group at 115 and 125 
GA compared to 145 GA in the periventricular white matter (p-value 0.0538 between the gestational 
ages, fig 19a) and in the subcortical white matter (p-value 0.1502 between the gestational ages, fig 
19b). 
19b 19a 
Figure 19a-c Percentage of Ki67-positive blood vessels out of the total number of blood vessels in a field of view in 
different brain regions studied. PFGR = P-value when the FGR group and the control group of the corresponding 
gestational age were compared. Ptime = P-value when the gestational ages in the same region were compared. NS = non-
significant. BV= blood vessel. Data presented as means ± SEM, significance set at P <0.05.  PVWM = periventricular 
white matter. SCWM= subcortical white matter. SVZ=subventricular zone. N =6-7 animals/group.  
19c 
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8. Discussion 
Germinal matrix and intraventricular hemorrhage (GMH-IVH) are one of the most severe brain 
injuries in late-preterm babies (93). This ontogeny study evaluated effects of chronic hypoxia on 
cerebral vasculature during late gestation using a fetal ovine model. We found nearly no differences 
between the the FGR group and the control group in the parameters we studied. Instead, our key 
finding is that there were significant differences in the morphology and number of blood vessels 
between the gestational ages regardless of growth restriction in several brain regions. The area, 
perimeter, length and breadth of the blood vessels appeared increased at 125 GA, compared to 115 
and 145 GA in the corresponding regions. The number of blood vessels appeared increased at 115 
GA in the subventricular zone and at 145 GA in the white matter regions, compared to the other 
gestational ages in the corresponding regions. These differences were most profound in the 
subcortical white matter and the subventricular zone. 
Since the increase in average blood vessel area observed in this study was not accompanied by 
increased blood vessel number at 125 GA, neovascularization (formation of new blood vessels) is not 
likely. Our results rather suggest expansion of the existing vessels occurring at 125 GA (~34 weeks 
GA in humans). Morphological adaptations we observed at this age could be an adaptive vascular 
response and correlate to previous studies reporting that GMH-IVH rates became significantly 
elevated in late-preterm births at 34-37 weeks of gestation (29).  
Contrary to our results, Mito et al (94) found no major differences in the blood vessel density and 
morphology in the white matter of the developing human brain (94). Nonetheless, Ballabh et al (89) 
showed that the vessel density in the human white matter increased only after 32 weeks of gestation 
and reached its peak at term gestation (89). Authors demonstrated also that the vessel density and 
percentage of blood vessel area increased from 16 to 32 weeks of gestation in the germinal matrix 
(89). This data is consistent with our results since we detected that the number of blood vessels 
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reached its peak at 145 GA (term gestation) in the white matter regions and at 115 GA (~ 31 weeks 
in humans) in the subventricular zone compared to the other gestational ages studied. The increase in 
blood vessel number we saw at 115 GA in the subventricular zone might be a result of high 
metabolic demand followed by angiogenetic response to ensure adequate vascular supply. Reason for 
this is that the subventricular zone volume is known to reach its maximum between 25-28 weeks of 
gestation (95).  
Vascular remodeling involves a highly coordinated break-down and build-up of the vascular 
basement membrane and endothelial tight junction proteins and this is mediated by matrix 
metalloproteinases (MMPs) (96). MMP9 is the most widely studied MMP under hypoxic-ischemic 
conditions both in human disease and in animal studies. We showed a significant difference between 
the gestational ages, regardless of growth restriction, in the percentage of MMP9-positive blood 
vessels in the subcortical white matter. This percentage appeared increased at 115 GA, compared to 
the other gestational ages in this region. We could also observe a trend of increased vascular 
proliferation in both FGR and control animals at 115 and 125 GA in the white matter regions, 
compared to 145 GA in these regions.  
When it comes to the differences between the FGR group and the control group, the only significant 
difference we saw was increased percentage of MMP9-positive blood vessels in control animals 
compared to FGR animals at 115 GA in the subventricular zone. No other significant differences 
between the FGR group and the control group appeared in any of the parameters, gestational ages or 
regions. Acute hypoxia has been shown to cause a shift of blood vessel size from smaller to larger 
blood vessels in the cerebral white matter of fetal sheep (75). The research group at Monash 
University has previously also studied how chronic hypoxia affects vascular morphology in FGR 
sheep in the same brain regions as in this study. They found that at full-term gestation, blood vessel 
density and area were significantly decreased in FGR individuals, compared to controls, in the 
corresponding brain regions (48). This is an interesting result since in the current study we did not, in 
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contrast, find any differences in blood vessel morphology between FGR individuals and control 
individuals. However, it should be noted that quantification of blood vessels in the present study was 
performed at x50 magnification compared to x200 magnification in the above mentioned study, 
which could be a source of variation in the results. In order to improve this study, we could image the 
sections stained with laminin again, this time using a higher magnification. This could help us 
increase accuracy in our results. 
If we wanted to expand this study or alter our focus, there are several ways. We could examine other 
regions in the brain or spinal cord, for example stain the grey matter in the cerebral cortex or 
hippocampus. Since the first intracerebral blood vessels in human telencephalon develop at 7 weeks 
of gestation (57), it might be interesting to study fetuses at even earlier gestational ages. The 
neuropathological outcome of FGR in fetal sheep varies depending on when the placental 
insufficiency is induced (43), so we could explore which differences late-onset and early-onset FGR 
causes in terms of cerebrovascular development.  
 
8.1 Limitations and strengths 
The major strength in this study was that we had a lot of tissue material for each staining, which 
produced sufficient data. For every animal, we took 9 or 12 images per section, and two sections 
were imaged for each animal. The averages that we ended up with for each animal were therefore 
accurate for that particular animal. In terms of the number of animals used in this study, the overall 
animal number was seven (N=7). We made sample size calculation using degree of freedom (97). 
According to this simple approach, our sample size was larger than necessary to prove statistically 
significant differences if such existed, so we had enough animals. 
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A potential weakness in our study is that we used three different animal cohorts that were produced 
several years apart from each other. Even though the surgery technique is well established, we cannot 
be sure that the animals were maintained identically. What also was challenging is that blood vessels 
have three-dimensional (3D) structure, which makes them demanding to study. We used thin coronal 
paraffin sections of the brain tissue, which prevents a full 3D analysis in a larger tissue volume. The 
results depend to a large extent on the direction of the blood vessels in each section, which in turn 
depends on the plane in which each section is cut. This may have caused some inaccuracies in our 
morphological calculations.  
With respect to the laboratory work, some of our stainings did not work as expected which resulted 
in fewer results than originally planned. Regarding the VEGF IHC, we found out that the secondary 
antibody was non-specific to use in sheep tissue. Since we lack data regarding VEGF, we have 
limited information about angiogenesis in the animals studied in this project. With regard to double 
fluorescence staining for endoglin and Ki67, it most likely failed because the secondary antibody was 
too old and had deteriorated due to it being exposed to light and temperature changes. We chose to 
stain with single-label, indirect Ki67 immunohistochemistry instead of double label. Single-label 
technique gives us no information about which cells are proliferating, so we do not know if it is 
endothelial cells, pericytes or other perivascular cells. We could amend this study by performing the 
protocol for double label fluorescence again, using a fresh secondary antibody, in order to measure 
blood vessels with specifically endothelial cell proliferation. Apart from the issues with protocols 
that did not work, we also lost some successfully stained sections because of tissue damage or when 
the staining was too faint or low quality to be imaged or quantified.  
When it comes to imaging of the laminin staining, the images used in this study were lower 
magnification than in a previous study in which our group stained with the same protocol (48), x50 
instead of previously used x200. This depended on that the slides were scanned in this project, and 
we took the pictures with an image viewing software instead of a physical microscope. As a result, 
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we made a misjudgement about which magnification would be appropriate. When lower 
magnification images were quantified, the software most likely picked up more background staining 
as blood vessels and missed some real blood vessels, compared to higher magnification. The overall 
intensity of staining may also have affected the quantification, and the software does not distinguish 
capillaries, veins and arteries from each other. The luminal and the endothelial area of the blood 
vessels could neither be measured with this approach.  
In addition, when taking the images, it was challenging to find the right regions because I lacked 
experience of microscopy work. We tried to image the same spot consistently in each section, but 
sometimes the tissue in that particular spot was damaged and the image had to be taken nearby. In 
addition, I was not aware of that the entire field of view was supposed to be occupied by tissue. 
Therefore, especially in the subventricular zone, the vessel number might be underestimated because 
some of the view was empty. Furthermore, the entire section was never imaged, only limited parts of 
it.   
Regarding the statistical analysis, almost all of our data sets passed the Shapiro-Wilk normality test. 
However, there were 3 sets of data that were not normally distributed: blood vessel area in the 
subventricular zone, blood vessel length in the subcortical white matter, and percentage of MMP9-
positive blood vessels in the subcortical white matter. This may have caused that we made more 
assumptions about the results than statistically appropriate.  
 
9. Conclusions and implications 
Our goal in this ontogeny study was to gain new knowledge about vascular maturation in the 
developing, growth-restricted brain during late gestation. In this way, we could contribute to the 
development of potential neuroprotective strategies to this vulnerable patient group in which IVH-
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GMH is a major concern. The current results obtained in this study suggest that fetal growth 
restriction does not disrupt cerebral vascular maturation in the fetal sheep brain. Nonetheless, we 
obtained some interesting results that are more likely related to normal, physiological vascular 
development and may therefore provide new insight in the context of cerebral vascular maturation in 
preterm infants. During development of the central nervous system, several cell types including 
pericytes, smooth muscle cells and astrocytes associate with blood vessels and contribute to 
maturation of the brain vasculature (97). This makes vascular development a complex topic to 
examine. The morphological changes in the cerebral vasculature we observed at 125 GA potentially 
indicate a vulnerable developmental window in the brain regions we studied. These changes would 
need to be related to developmental changes and the whole neurovascular unit and the other 
angiogenetic growth factors should be investigated at this gestational age in FGR and control 
animals. By doing this, we could potentially identify if FGR affects the vulnerability of these 
particular brain regions to injury. 
 
10. Blodkärlsutveckling i hjärnan hos fårfoster utsatta för 
tillväxthämning i livmodern - populärvetenskaplig sammanfattning  
Brist på syre och näring under fostertiden leder till tillväxthämning, och fostret föds med lägre 
födelsevikt. Oftast orsakas tillväxthämningen av att moderkakan inte fungerar optimalt eftersom det 
är därifrån fostret får syre och näring via blodkärl. Det ger konsekvenser i många olika organ i 
kroppen. Det kan bland annat leda till att hjärnan inte utvecklas normalt och att barnet får sämre 
rörelseförmåga, inlärningsförmåga och presterar sämre i skolan. I den här studien har vi undersökt 
hur långvarig brist på syre och näring under graviditet påverkar utvecklingen av blodkärl i hjärnan 
hos fostret. Studien har genomförts på en medicinsk forskningsinstitution i Melbourne, Australien. 
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10.1 Metod 
Vi använde oss av en väletablerad och beprövad modell av fårfoster. Ett kirurgiskt ingrepp utfördes 
när ca 70 % av graviditeten hade passerat. Ingreppet orsakade försämrad funktion av moderkakan 
som ledde till att fostret eller fostren utsattes för brist på syre och näring i livmodern. En 
tillväxthämmad grupp av foster avlivades sedan när ca 80 % av graviditeten hade passerat, en annan 
grupp när ca 85 % hade passerat, och en tredje grupp avlivades efter fullgången graviditet. Varje 
tillväxthämmad grupp jämfördes med en kontrollgrupp, som bestod av foster med normalfungerande 
moderkakor och som genomgått lika långa graviditeter som fostren i den tillväxthämmade gruppen.  
Efter avlivningen opererades hjärnorna ut ur fostren och snittades i tunna snitt. Tre olika regioner i 
hjärnan studerades. Snitten färgades med en laboratorieteknik för att kunna visualisera kärl samt två 
proteiner relaterade till kärlutvecklingen. Färgningarna undersöktes med ett mikroskop och 
beräkningar gjordes såväl manuellt som med hjälp av ett datorprogram. 
 
10.2 Resultat 
Vi såg mycket sparsamma skillnader mellan den tillväxthämmade gruppen och kontrollgruppen. När 
vi jämförde graviditetslängder, såg vi att efter 80% av en fullgången graviditet fanns det ökning i ett 
kärltillväxtfrämjande protein i en av hjärnregionerna i fosterhjärnorna. Efter 85 % av en fullgången 
graviditet var kärlen generellt sett bredare, längre och hade större yta och omkrets. Vid fullgången 
graviditet var antalet kärl ökat i två av hjärnregionerna, jämfört med tidigare under graviditeten. 
Dessa fynd var likadana hos såväl de tillväxthämmade fostren som fostren med normal graviditet.   
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10.3 Studiens användbarhet 
Hjärnan hos ett tillväxthämmat foster är sårbar och utvecklas inte normalt när den inte har fullgod 
tillgång till syre och näring. Dessa barn föds ofta också för tidigt vilket komplicerar situationen 
ytterligare. Konsekvenserna kan bli långvariga vad gäller bland annat beteende och rörelseförmåga. 
Enligt den här studien tar hjärnans blodkärl inte skada av tillväxthämning, men det finns fler aspekter 
att undersöka inom ämnet. Däremot har vi sett skillnader i kärlutvecklingen över tid i graviditeten. 
Denna kunskap kan hjälpa forskningen i utvecklingen av potentiella behandlingar för att förebygga 
och åtgärda hjärnskador hos tillväxthämmade och för tidigt födda bebisar. 
 
11. Acknowledgements 
I would like to thank my supervisors Prof Carina Mallard, A/Prof Suzie Miller and Dr Margie 
Castillo-Melendez for your great advice and patience. I would also like to show my gratitude to the 
Miller-Jenkins laboratory group at the Ritchie Center at Hudson Institute of Medical Research for 
welcoming me into their group and to Dr Kirstin Elglass for her technical assistance. Thank you, 
Stena Foundation and the Sahlgrenska Academy, for the scholarships that helped me finance my trip 




   52  
12. Appendix 
Detailed protocols for the five immunohistochemical stainings performed in this study are described 
below.  
 
12.1 Laminin single-label, indirect immunohistochemistry  
1. Bake the slides in 56 °C oven for one hour.  
2. The following day, dewax the slides 2x5 minutes (min) in xylene and rehydrate in 2x5 minutes in 
100 % ethanol and 5 minutes in 70 % ethanol. Rehydrate further for 10 minutes in phosphate-
buffered saline (PBS) containing 0.1 % tween 20 (pH 7.4).  
3. Apply PAP (peroxidase-anti-peroxidase) pen around tissue sections.  
4. Cover the sections with 20 µg/ml Proteinase K (200 µl in TE Buffer, pH 8.0 containing NO 
detergent) and incubate for 30 minutes at 37 °C humidified chamber. 
5. Allow sections to cool at room temperature for 20 minutes and rinse in PBS for 3x5 minutes.  
6. Block endogenous peroxidases with 0.3 % hydrogen peroxide in 50 % methanol for 15 minutes at 
room temperature.  
7. Rinse the sections were rinsed in PBS 3x5 minutes and block with DAKO protein free blocking 
solution for 45 minutes at room temperature to block non-specific binding. 
8. Blot excess serum blocker was blotted from sections and incubate sections with rabbit anti-laminin 
IgG (1:200 dilution) made up in PBS overnight at 4 °C in a humidified box. 
9. On the following day, rinse the sections in PBS for 3x5 minutes, incubated with a goat anti-rabbit 
biotinylated secondary antibody (1:200) for 1 hour at room temperature. 
10. Rinse the sections in PBS for 3x5 minutes and subsequently incubate with streptavidin-
horseradish peroxidase (streptavidin-HRP) 1:200 reagent for 45 minutes at room temperature and 
rinsed in PBS 3x5 minutes.  
11. Incubate the sections with 3,3’ diaminobenzidine (DAB) complex (1/10) for 15 minutes at room 
temperature to allow visualisation of the immunostaining. Mix one tablet with 10ml water, vortex 
until the tablet was dissolved and add 3µl of hydrogen peroxide before applying 200µl to each 
section.  
12. Wash the sections were then washed in running tap water for 2 minutes. Rehydrate through a 
series of ethanol baths (70% ethanol for 2 minutes, 2x100% ethanol for 2 minutes each) and clear in 
xylene 2x5 minutes. Coverslip with DPX mounting medium. 
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12.2 Double label fluorescence: endoglin and Ki67 immunohistochemistry 
1. Bake the sections in 56 °C oven for one hour and dewax in xylene 2x5 minutes 
2. Wash the sections in 100 % ethanol for 2x 5 minutes and in 70 % ethanol for 5 minutes. Rehydrate 
for 5 minutes in phosphate-buffered saline (PBS) containing 0.3% Triton X 100 (PBS-TX) (pH 7.4).  
3. Antigen retrieval part 1: heat tissue sections in a microwave oven in citrate buffer at pH 6.0 for 10 
minutes at 100 °. Cool for 10 minutes in hot buffer and rinsed in 3x5 minutes in PBS. 
4.  Block endogenous peroxidase with 3 % H2O2 in methanol for 5 minutes at room temperature.  
5. Rinse the sections in PBS for 3 x 5 minutes. 
6. Incubate with sodium borohydride (10mg/ml) in 0.01 M PBS 2x10 minutes and wash in PBS 3x5 
minutes to minimize autofluorescence. 
7.  Incubate the sections in DAKO protein free blocker for 40 minutes at room temperature. 
8. Incubate with a mixture of mouse monoclonal anti-endoglin primary antibody (1/50 millipore) and 
rabbit monoclonal anti-Ki-67 antibody (1:100) made up in 0.1 M PBS overnight at 4 °. 
9. On the following day, wash the sections 3x5 minutes in PBS.  
10. Incubate protected from light with a mix of fluorescence labelled secondary antibody, goat anti-
mouse Alexa 594 (1/1000), and goat anti-rabbit Alexa A488 (1/1000). 
11. Wash the sections in PBS 3x5 minutes and allow to dry. 
12. Coverslip with Vectashield aqueous mounting media and store protected from light in the fridge.  
 
12.3 VEGF single-label, indirect immunohistochemistry  
1. Rinse the sections were rinsed in PBS-TX (triton X 1%) for 10 minutes.  
2. Antigen retrieval was performed by heating the sections 3x10 minutes bursts in the microwave in 
citric acid buffer at pH 6 and cooled for 20 minutes at room temperature.  
3. Rinse the sections in PBS for 3 x15 minutes.  
4. Peroxidase blocking: incubate sections in peroxidase blocking solution for 10 minutes at room 
temperature. Reduce unspecific background staining by rinsing the sections in  0.3 % H2O2. 
6. Rinse the sections in PBS for 3x5 minutes. Serum blocking was performed by incubating sections 
in DAKO protein free blocker for 60 minutes at room temperature.  
7. Incubate the sections in mouse-monoclonal anti-VEGF-A primary antibody (1/200) in PBS 
overnight at 4 °C. 
8. The following day, rinse the sections in PBS 3x5 minutes.  
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9. Incubate the sections in the secondary antibody goat-anti-mouse (1/200) in PBS for one hour at 
room temperature. 
10. Rinse the sections in PBS for 3x5 minutes and incubate with streptavidin-HRP (1/200) for one 
hour at room temperature. 
11. Rinse the sections in PBS for 3x5 minutes and incubate with DAB complex (1/10) for 5-10 
minutes. Mix one tablet with 10ml water, vortex until the tablet is dissolved and add 3µl of hydrogen 
peroxide before applying 200µl to each section.  
12. Rinse the sections in PBS 3x5 minutes and rinse in running tap water for 2-5 minutes.  
13. Rehydrate the sections through a series of 95% ethanol for 1 minute, 100 % ethanol for 2x3 
minutes and clear in xylene for 2 x 5 minutes. Coverslip the sections with DPX mounting medium.  
 
12.4 MMP9 indirect, single-label immunohistochemistry 
1. Bake the sections in 60 °C oven for one hour.  
2. The following day, wash the sections 2x in 100 % ethanol for 5 minutes and in 70 % ethanol for 5 
minutes. 
3. Rehydrate the sections for 10 minutes in PBS containing 0.1 % Tween 20 (pH 7.4). Apply Pap pen 
around tissue sections.  
4. Cover the sections with 20 µg/ml Proteinase K and incubate for 30 minutes at 37 °C  humidified 
chamber.  
5. Allow the sections to cool at room temperature for 20 minutes and rinse in PBS for 3x5 minutes. 
6. Block endogenous peroxidases with 0.3 % hydrogen peroxide in 50 % methanol for 10 minutes at 
room temperature. 
7. Rinse the sections in PBS 3x5 minutes and block with DAKO protein free blocking solution for 45 
minutes at room temperature.  
8. Blot excess serum blocker from sections and incubate the sections with rabbit polyclonal MMP9 
(1:100 dilution) made up in PBS overnight at 4 °C in a humidified box.  
9. On the following day, rinse the sections in PBS 3x5 minutes and incubate with biotinylated goat 
anti-rabbit IgG (1:200 dilution) for 55 minutes at room temperature.  
10. Rinse the sections in PBS 3x5 minutes and incubate with streptavidin-HRP (1/200) reagent for 45 
minutes at room temperature.  
11. Rinse the sections in PBS 3-5 minutes and incubate with DAB complex (1/10) for 15 minutes at 
room temperature. Mix one tablet with 10ml water, vortex until the tablet was dissolved and add 3µl 
of hydrogen peroxide before applying 200µl to each section. 
12. Rinse the sections in PBS 3 x 5 min and faintly counterstain by dipping the sections in  0.1% 
Cresyl Violet.  
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13. Rinse the sections quickly in tap water to remove excess stain and wash in 70% ethanol for 5 
min. This is performed in order to allow identification of blood vessels without drowning out the 
brown DAB chromagen used to visualize MMP9 immunoreactivity.  
14. Wash the sections in running tap water for 1 minute or more and dehydrate by bathing sections in 
70 % EtOH for 2 minutes, and 2x100 % EtOH for 2 minutes each. Clear the sections in xylene 2x5 
minutes each and coverslip with DPX mounting medium.  
 
12.5 Ki67 single-label, indirect immunohistochemistry  
1. Dewax the sections 3 x 5 min in xylene and rehydrate in 0.05M Tris-buffered saline containing 0.3 
% triton x100 (PBS-TX) (pH 7.6).  
2. Antigen retrieval: heat the slides in citric acid buffer (pH 6) for 4x5 min followed by 10 min cooling 
in the buffer.  
3. Wash the sections 3 x 5 in PBS-TX at room temperature.  
4. Quench endogenous peroxidases by placing slides in mailers and using 3% hydrogen peroxide in 
water for 10 min at room temperature. Wash the sections in PBS 3 x 5min. Draw PAP pen around each 
section. 
5. Transfer the sections to an incubation box and incubate in DAKO protein free blocker 45 min at 
room temperature (200µl per section).  
6. Incubate the sections with rabbit monoclonal antibody against Ki67 in PBS at room temperature 
1/100 at 4oC overnight (200µl per section). 
7. The following day, rinse the sections in PBS 3 x 5 min. 
8.  Incubate the sections with biotinylated goat anti-rabbit secondary antibody (1/200) for 1 hour at 
room temperature (200µl per section).  
9. Rinse the sections in PBS 3 x 5 min and incubate with strep-HRP (1/200) for 1 hour at room 
temperature (200µl per section). 
10. Rinse the sections in PBS 3 x 5 min and incubate with DAB complex (1/10) for 5-15 min. Mix one 
tablet with 10ml of water, vortex until the tablet is dissolved and add 3µl of hydrogen peroxide before 
applying 200 µl to each section. 
11. Rinse the sections in PBS 3 x 5 min and faintly counterstain by dipping the sections in 0.1% 
Cresyl Violet. This is performed in order to allow identification of blood vessels without drowning 
out the brown DAB chromagen used to visualize Ki67 immunopositive cells.  
12. Rinse the sections quickly in tap water to remove excess stain and wash in 70% ethanol for 5 
min. Dehydrate the sections through 2x3min changes of absolute ethanol and clear in xylene 2x3 
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